A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
A Phase 4 Multicenter, Randomized, Open-Label, Interventional Study With Pragmatic Elements Investigating the Effectiveness of Tirzepatide Once Weekly Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes in a Real-World Setting
Eli Lilly and Company
3,000 participants
Nov 24, 2025
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Participation in the study will last about 260 weeks.
Eligibility
Inclusion Criteria4
- Have a body mass index ≥30 and ≤34.9 kilogram per square meter (kg/m2)
- Have an increased waist to height ratio (defined by \>0.5)
- Have at least one weight related comorbid condition
- Have had at least one attempt to lose weight with lifestyle intervention (diet and physical activity)
Exclusion Criteria2
- Have type 1 diabetes, type 2 diabetes, or any other types of diabetes
- Have had a change in body weight of greater than 5 kilograms (11 pounds) within 90 days prior to screening
Interventions
Administered SC
Standard of care
Locations(25)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07247084